| Literature DB >> 24191158 |
Anne-Lotte W M Coolen1, Anique M J van Oudheusden, Hugo W F van Eijndhoven, Tim P F M van der Heijden, Rutger A Stokmans, Ben Willem J Mol, Marlies Y Bongers.
Abstract
Introduction. Sacrocolpopexy is a generally applied treatment for vault prolapse which can be performed laparoscopically or by open laparotomy. Methods. Between October 2007 and December 2012, we performed a multicenter prospective cohort study in 2 university and 4 teaching hospitals in the Netherlands. We included patients with symptomatic posthysterectomy vaginal vault prolapse requiring surgical treatment, who either had abdominal or laparoscopic sacrocolpopexy. We studied surgery related morbidity, which was divided in pre-, peri-, and postoperative characteristics. Results. We studied 85 patients, of whom 42 had open abdominal and 43 laparoscopic sacrocolpopexy. In the laparoscopic sacrocolpopexy group, estimated blood loss was significantly less compared to the abdominal group: 192 mL (±126) versus 77 mL (±182), respectively (P ≤ .001). Furthermore, hospital stay was significantly shorter in the laparoscopic group (4.2 days) as compared to the abdominal group (2.4 days) (P ≤ .001). The overall complication rate was not significantly different (P = .121). However there was a significant difference in favor of the laparoscopic group in peri- and postoperative complications requiring complementary (conservative) treatment and/or extended admittance (RR 0.24 (95%-CI 0.07-0.80), P = .009). Conclusion. Laparoscopic sacrocolpopexy reduces blood loss and hospital stay as compared to abdominal sacrocolpopexy and generates less procedure related morbidity.Entities:
Year: 2013 PMID: 24191158 PMCID: PMC3804373 DOI: 10.1155/2013/528636
Source DB: PubMed Journal: Obstet Gynecol Int ISSN: 1687-9597
Baseline characteristics (ITT-analysis).
| Laparoscopic sacrocolpopexy | Open abdominal sacrocolpopexy |
| |
|---|---|---|---|
| Age (years) | |||
| Median (IQR) | 66.2 (61.2–72.7) | 67.6 (64.1–73.6) |
|
| Body mass index (kg/m2) | |||
| Median (IQR) | 25.4 (22.5–27.4) | 25.6 (23.9–28.3) |
|
| Parity ( |
| ||
| 0 | 2.4% (1/42) | 0.0% (0/40) | |
| 1 | 7.1% (3/42) | 7.5% (3/40) | |
| 2 | 42.9% (18/42) | 45.0% (18/40) | |
| 3 | 40.5% (17/42) | 25.0% (10/40) | |
| ≥4 | 7.1% (3/42) | 22.5% (9/40) | |
| Menopausal status ( |
| ||
| Premenopausal | 2.3% (1/44) | 4.7% (2/43) | |
| Postmenopausal | 97.7% (43/44) | 95.3% (41/43) | |
| Incontinence ( |
| ||
| None | 59.5% (25/42) | 51.2% (21/41) | |
| Stress | 4.8% (2/42) | 7.3% (3/41) | |
| Urge | 14.3% (6/42) | 7.3% (3/41) | |
| Combined | 21.4% (9/42) | 34.1% (14/41) | |
| Estrogens use ( |
| ||
| None | 94.3% (33/35) | 82.4% (28/34) | |
| Local/Systemic | 5.7% (2/35) | 17.6% (6/34) | |
| History of gynecological surgery ( |
| ||
| TVH only | 38.1% (16/42) | 27.5% (11/40) | |
| TVH and ACR | 9.5% (4/42) | 5.0% (2/40) | |
| TVH and PCR | 2.4% (1/42) | 20.0% (8/40) | |
| TVH and ACR/PCR | 28.6% (12/42) | 12.5% (5/40) | |
| TVH, later ACR and mesh | 2.4% (1/42) | 0.0% (0/40) | |
| TAH, ACR and later PCR | 0.0% (0/42) | 2.5% (1/40) | |
| TAH only | 9.5% (4/42) | 27.5% (11/40) | |
| TAH and PCR | 2.4% (1/42) | 2.5% (1/40) | |
| Laparoscopic hysterectomy | 4.8% (2/42) | 0.0% (0/40) | |
| Supracervical hysterectomy | 2.4% (1/42) | 0.0% (0/40) |
TVH: transvaginal hysterectomy, TAH: total abdominal hysterectomy.
ACR: anterior colporrhaphy, PCR: posterior colporrhaphy.
Preoperative POP-Q.
| Open abdominal sacrocolpopexy | Laparoscopic sacrocolpopexy |
| |
|---|---|---|---|
| Aa | −0.3 ± 1.8 | −0.5 ± 1.6 |
|
| Ba | 0.6 ± 2.8 | 0.6 ± 2.3 |
|
| C | −0.3 ± 4.2 | 1.0 ± 2.3 |
|
|
| |||
| GH | 3.7 ± 0.8 | 3.7 ± 0.8 |
|
| PB | 3.1 ± 0.5 | 2.5 ± 0.9 |
|
| TVL | 7.9 ± 1.5 | 7.7 ± 1.3 |
|
|
| |||
| Ap |
−0.7 ± 1.7 | −1.2 ± 1.9 |
|
| Bp | 0.1 ± 2.7 | −0.4 ± 2.5 |
|
| D | — | — | — |
Perioperative data (PP-analysis).
| Laparoscopic sacrocolpopexy | Open abdominal sacrocolpopexy |
| |
|---|---|---|---|
| Operative time (minutes) | |||
| Median (IQR) | 120 (110–140) | 120 (105–132) |
|
| Estimated blood loss (mL) | |||
| Median (IQR) | 50 (10–100) | 200 (100–250) |
|
| Hospital stay (days) | |||
| Median (IQR) | 2 (2-3) | 4 (3–5) |
|
Patients with perioperative and postoperative complications (PP-analysis).
| Laparoscopic sacrocolpopexy | Open abdominal sacrocolpopexy |
| |
|---|---|---|---|
| Perioperative complications |
| ||
| One or more complications | 11.1% (5) | 7.1% (3) | |
| Severe adhesions | — | 2.4% (1) | |
| Bladder lesion | 4.7% (2) | 4.8% (2) | |
| Bleeding | 4.7% (2) | — | |
| Alternative mesh fixation | 2.3% (1) | — | |
| Postoperative complications |
| ||
| One or more complications | 14.0% (6) | 28.6% (12) | |
| Fatal bowel perforation | — | 2.4% (1) | |
| Wound dehiscence | — | 4.8% (2) | |
| Pulmonary embolism | — | 2.4% (1) | |
| Ileus | — | 7.1% (3) | |
| Abdominal wall hematoma | 2.3% (1) | 4.8% (2) | |
| Cardiac complication | 4.7% (2) | — | |
| Delirium | — | 2.4% (1) | |
| Wound infection | 2.3% (1) | — | |
| Urinary tract infection | — | 2.4% (1) | |
| Urinary retention | 4.7% (2) | 4.8% (2) | |
| One or more treated complications* | 7.0% (3) | 28.6% (12) |
|
| One or more major complications** | — | 7.1% (3) |
|
*Complications due to the surgical intervention requiring complementary (conservative) treatment and/or extended admittance.
**According to the Dutch complication registration of the NVOG [11].
Patients with complications 6 weeks postoperative (PP-analysis).
| Laparoscopic sacrocolpopexy | Open abdominal sacrocolpopexy |
| |
|---|---|---|---|
| Complications 6 weeks postoperative |
| ||
| One or more complications | 16.7% (7) | 21.4% (9) | |
| Constipation | 11.6% (5) | 7.1% (3) | |
| De novo stress incontinence | 2.3% (1) | 7.1% (3) | |
| De novo urinary incontinence | 2.3% (1) | — | |
| Recurrent urinary tract infections | — | 4.8% (2) | |
| Bothersome pain around incision | — | 2.4% (1) |